CGTLive®’s Weekly Rewind – March 15, 2024

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

According to Federal Register notices, the guidance documents are updated versions of drafts originally published in March 2022.

The McCaw Endowed Chair of Muscular Dystrophy at University of Washington discussed his research career with muscular dystrophies.

The positive DSMB recommendation came after no participants were found to experience any serious adverse events from the therapy.

The assistant professor in the department of pediatrics at the University of Florida College of Medicine discussed also discussed the latest results announced from the phase 2 portion of the PRISM study.

Verve Therapeutics plans to expand evaluations into the US after an IND clearance was delayed by a clinical hold.